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For Kansas State University biochemist Anna Zolkiewska, the battle against breast cancer starts 
in the laboratory.
By studying breast cancer stem cells, Zolkiewska is 
working to prevent cancer recurrence and metastasis — 
the major causes of death among breast cancer patients. 
Around 40,000 U.S. women die from breast cancer every 
year, according to the American Cancer Society.
Zolkiewska, associate professor of biochemistry 
and molecular biophysics, is using a four-year $1.245 
million grant from the National Cancer Institute — 
at the National Institutes of Health — to study a 
promising breast cancer marker called ADAM12 and 
its role in breast tumor-initiating cells, or BTICs. Her 
research also has received support from the university’s 
Johnson Cancer Research Center, which is a team of 
multidisciplinary faculty scientists who perform basic 
cancer research.
Breast tumor-initiating cells — known as cancer 
stem cells — drive breast tumor progression and tumor 
recurrence or metastasis. Zolkiewska’s research can 
provide clinicians with better diagnostic tools, new cancer 
prevention strategies and improved treatment options.
Researcher turns to biochemistry to 
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“Our studies strive to produce new research and 
diagnostic tools for detection of breast tumor-initiating 
cells and to develop new therapies to target these cells,” 
Zolkiewska said.
While current treatments for breast cancer — such 
as surgery, chemotherapy and radiation therapy — can 
destroy the majority of tumor cells, these treatments cannot 
eradicate cancer stem cells. Current treatments also have 
many negative side effects.
“The problem is that cancer stem cells are present 
in very low amounts,” Zolkiewska said. “They are 
difficult to detect. But we know that they exist and they 
are practically resistant to chemotherapy and radiation 
therapy.”
Even when chemotherapy appears to work, breast 
tumor-initiating cells can cause tumors to re-emerge or 
metastasize to bones, lungs or the brain.
“Once metastasis occurs, the chances to cure the 
patient decrease dramatically,” Zolkiewska said. “It is 
absolutely critical to be able to identify cancer stem 
cells and to find more effective treatments against 
them.”
Zolkiewska is focusing on ADAM12, which is a 
member of the ADAM family of cell-surface disintegrin-
metalloproteases. Unlike other current cancer markers 
— which are found in both healthy and cancerous 
tissues — ADAM 12 is not expressed in healthy human 
mammary glands.
Zolkiewska’s work suggests that ADAM12 is induced 
precisely in breast cancer stem cells. ADAM12 can be 
used with existing markers for improved detection, 
isolation and characterization of breast tumor-initiating 
cells in the laboratory.
Long term, Zolkiewska wants to understand 
exactly how ADAM12 functions in cancer stem cells 
at the molecular level. She also wants to know how 
breast tumor-initiating cells differ from other breast 
tumor cells.
“We might be able to use ADAM12 to develop 
targeted therapies to eradicate cancer stem cells with 
fewer side effects, which is of great importance,” 
Zolkiewska said. “Ultimately, we hope we can improve 
the quality of life for breast cancer patients.”
Zolkiewska also is completing a three-year $444,000 
grant from the National Institutes of Health for research 
on mutations in the ADAM12 gene. Her research team 
includes Hui Li, postdoctoral researcher; Sara Duhachek 
Muggy, doctoral student in biochemistry; and Yue Qi, 
doctoral student in biochemistry.
Hui Li and Sara Duhachek Muggy
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